Health and Healthcare Systems

The Zika virus could be used to attack brain tumours

Manufacturing Associate Theodore Szmurlo views a cell sample with a microscope as he works in the cell culture room where they are working on developing a vaccine for the Zika virus based on production of recombinant variations of the E protein from the Zika virus at the Protein Sciences Inc. headquarters in Meriden, Connecticut, U.S., June 20, 2016. Picture taken June 20, 2016. REUTERS/Mike Segar - S1BEUEYZFVAC

Scientists have found that the Zika virus can kill glioblastoma stem cells. Image: REUTERS/Mike Segar

Karla Lant
Share:
Our Impact
What's the World Economic Forum doing to accelerate action on Health and Healthcare Systems?
The Big Picture
Explore and monitor how Global Health is affecting economies, industries and global issues
A hand holding a looking glass by a lake
Crowdsource Innovation
Get involved with our crowdsourced digital platform to deliver impact at scale
Stay up to date:

Global Health

In brief

Researchers found that the Zika virus can kill glioblastoma stem cells, which make the most common type of brain tumors both deadly and difficult to treat. Their discovery may lead to a complementary treatment regimen with chemotherapy and radiation.

Zika kills glioblastoma cells

New research shows that although Zika virus can devastate the fetal brain, causing infants to be born with microcephaly, this same destructive power could be an effective treatment for a deadly form of brain cancer called glioblastoma. Scientists conducting the study found that the virus kills malignant brain cancer stem cells — cells which are most resistant to typical cancer treatments. If further developed and validated, this treatment could dramatically improve the outlook for patients with glioblastoma, which is usually fatal within one year of diagnosis.

Every year, approximately 12,000 people in the US are diagnosed with glioblastoma, the most common type of brain cancer. If previously unfamiliar with the illness, it might sound familiar as Senator John McCain is among those diagnosed this year. Despite the aggressive nature of the standard treatment regimen for glioblastoma, which includes surgery followed by radiation and chemotherapy, most tumors recur within six months. This is because glioblastoma stem cells often survive treatment, continuing to divide and produce new tumor cells, making glioblastoma so deadly; approximately 95 percent of patients die within five years of diagnosis, and more than half die within the first 15 months.

Image: Zhu Zhu

This research team observed that glioblastoma stem cells behaved much like neuron progenitor cells do, in that both kinds of cells are neurological and have an almost limitless ability to create new cells. Since Zika virus targets and kills neuro progenitor cells, they decided to see if it might also be able to target and kill glioblastoma stem cells. The team infected glioblastoma tumors with two different strains of the Zika virus, and found that both strains infected and killed the cancer stem cells while mostly avoiding other cells in the tumors. The researchers then injected Zika virus into brain tumors in mice to test whether the virus could treat cancer in a living animal, and found that the tumors were significantly smaller in the Zika-treated mice, who survived longer than the control group.

Complementary treatments

These results suggest that Zika virus infection and tradition radiation and chemotherapy treatments might have complementary effects. The former targets stem cells but leaves the rest of the tumor, however, the latter kills the tumor cells and can miss the stem cells. “We see Zika one day being used in combination with current therapies to eradicate the whole tumor,” Washington University School of Medicine assistant professor of medicine and of neurology Milan G. Chheda, MD said in a press release.

It may seem scary to intentionally infect people with Zika virus; to treat tumors the virus would be injected directly into the brain, probably during surgery to remove the primary tumor and avoid triggering an immune response. However, in adults, Zika is far safer than it is in children and babies because adult brains have very few neuro progenitor cells.

The researchers have also taken steps to render the virus safer, testing it in other brain tissue and introducing mutations that weaken the virus’s ability to fight immune responses. This change makes the virus able to grow in unhealthy tumor cells, but unable to survive the robust antiviral response of healthy cells. “We’re going to introduce additional mutations to sensitize the virus even more to the innate immune response and prevent the infection from spreading,” Michael S. Diamond, MD, Ph.D., the Herbert S. Gasser Professor of Medicine at Washington University School of Medicine and the study co-senior author, said in the press release. “Once we add a few more changes, I think it’s going to be impossible for the virus to overcome them and cause disease.”

Don't miss any update on this topic

Create a free account and access your personalized content collection with our latest publications and analyses.

Sign up for free

License and Republishing

World Economic Forum articles may be republished in accordance with the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Public License, and in accordance with our Terms of Use.

The views expressed in this article are those of the author alone and not the World Economic Forum.

Related topics:
Health and Healthcare SystemsFourth Industrial Revolution
Share:
World Economic Forum logo
Global Agenda

The Agenda Weekly

A weekly update of the most important issues driving the global agenda

Subscribe today

You can unsubscribe at any time using the link in our emails. For more details, review our privacy policy.

Market failures cause antibiotic resistance. Here's how to address them

Katherine Klemperer and Anthony McDonnell

April 25, 2024

2:12

About Us

Events

Media

Partners & Members

  • Join Us

Language Editions

Privacy Policy & Terms of Service

© 2024 World Economic Forum